ATE171192T1 - Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer - Google Patents

Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer

Info

Publication number
ATE171192T1
ATE171192T1 AT93912916T AT93912916T ATE171192T1 AT E171192 T1 ATE171192 T1 AT E171192T1 AT 93912916 T AT93912916 T AT 93912916T AT 93912916 T AT93912916 T AT 93912916T AT E171192 T1 ATE171192 T1 AT E171192T1
Authority
AT
Austria
Prior art keywords
glu
lys
leu
pct
asp
Prior art date
Application number
AT93912916T
Other languages
English (en)
Inventor
Maryvonne Rosseneu
Robert Brasseur
Robert Deleys
Christine Labeur
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE171192T1 publication Critical patent/ATE171192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT93912916T 1992-06-12 1993-06-08 Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer ATE171192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92401621 1992-06-12

Publications (1)

Publication Number Publication Date
ATE171192T1 true ATE171192T1 (de) 1998-10-15

Family

ID=8211669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912916T ATE171192T1 (de) 1992-06-12 1993-06-08 Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer

Country Status (7)

Country Link
US (1) US5733879A (de)
EP (1) EP0644897B1 (de)
JP (1) JPH07507554A (de)
AT (1) ATE171192T1 (de)
CA (1) CA2137814A1 (de)
DE (1) DE69321118T2 (de)
WO (1) WO1993025581A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344822A (en) * 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
DE69636907T2 (de) * 1995-11-09 2007-11-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
JP4644383B2 (ja) * 2001-05-11 2011-03-02 日本分光株式会社 タンパク質二次構造の面分布測定方法及び装置
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
EP1812474B1 (de) 2004-10-15 2010-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
EP1890715A4 (de) * 2005-04-29 2009-10-28 Univ California Peptide und peptidmimetika für die behandlung durch entzündliche reaktion charakterisierter pathologien
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8163699B2 (en) 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
EP2195331B1 (de) * 2007-08-28 2013-11-20 Uab Research Foundation Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
AU2010213568B2 (en) 2009-02-16 2014-11-20 Cerenis Therapeutics Holding Sa Apolipoprotein A-I Mimics
EP2517013A4 (de) * 2009-12-23 2013-07-17 Artery Therapeutics Inc Diagnose und behandlung von erkrankungen im zusammenhang mit defizientem reversem cholesterintransport
JP5860052B2 (ja) * 2010-08-30 2016-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ テトラネクチン−アポリポタンパク質ａ−ｉ、それを含有する脂質粒子及びその使用
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E

Also Published As

Publication number Publication date
EP0644897B1 (de) 1998-09-16
US5733879A (en) 1998-03-31
DE69321118D1 (de) 1998-10-22
EP0644897A1 (de) 1995-03-29
AU4324093A (en) 1994-01-04
DE69321118T2 (de) 1999-06-02
CA2137814A1 (en) 1993-12-23
WO1993025581A1 (en) 1993-12-23
AU679180B2 (en) 1997-06-26
JPH07507554A (ja) 1995-08-24

Similar Documents

Publication Publication Date Title
DE69321118D1 (de) Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer
Watterson et al. The complete amino acid sequence of the Ca2+-dependent modulator protein (calmodulin) of bovine brain.
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
Schofield et al. Procollagen-a precursor form of collagen
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
DE69931793D1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
PT975761E (pt) Interferao beta humano recombinante com solubilidade melhorada
DE69009476D1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
DE3688324D1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE3850878D1 (de) Elastase-inhibierungspolypeptide und verfahren zur herstellung durch genetische rekombination.
DE69030920D1 (de) Verfahren zur herstellung von pai-2
FI942442A0 (fi) Proteiinien tuotto 7B2-proteiinia käyttäen
DK0703923T3 (da) Faktor VII afledte peptider
ATE253639T1 (de) Verfahren zur herstellung von peptiden
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
Dalcol et al. Convergent synthesis of repeating peptides (Val-X-Leu-Pro-Pro-Pro) 8 adopting a polyproline II conformation
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
ATE152772T1 (de) Verhindern von spaltung von n-terminalen aminosäuren durch endogene aminopeptidasen während die expression von fremden genen in bakterien
ATE248806T1 (de) N-3, 3-dimethylbutyl-l-asparaginsäure und ihre ester, verfahren zur herstellung dieser und das verfahren um daraus n-(n-(3,3-dimethylbutyl)-l- alpha-aspartyl)-l-phenylalanin-1-methylester herzustellen
ATE215811T1 (de) Verfahren zur aminosäuregewinnung aus proteinen und verwendung derselben aminosäurehaltigen produkte
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
DE69834929D1 (de) Verwendung eines organspezifischen ernährungmittels

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee